Sanofi

Dow Technology Investments LLC

Matthias Schaefer

Dieter Kadereit

Thomas Huebschle

Stephanie Hachtel

Katrin Hiss

Josef Pernerstorfer

Marcel Patek

Alena Safarova

Axel Dietrich

Werngard Czechtizky

Hartmut Strobel

Aleksandra Weichsel

L Charlie Chen

Andreas Gille

Heinz-Werner Kleemann

Christopher P Christenson

Paulus Wohlfart

Harvey E Andresen

Charles William Lipp

John R Mayer

Charles W Lipp

Victor R Fey

Michael L Hutchison

Laurence G Britton

Philip Janiak

Thomas J Kling

Michael J Rangitsch

Silke Haag-Diergarten

Bruno Poirier

Ashfaq Parkar

Sabine Gratzer

Véronique Briand

Veronique Briand

{4-[5-(3-chloro-phenoxy)-oxazolo[5,4-d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid or a pharmaceutically acceptable salt thereof for use in the prevention or treatment of AKI (acute kidney injury). Medicament and pharmaceutical composition thereof.

{4-[5-(3-chloro-phenoxy)-oxazolo[5,4-d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid for use in the prevention or treatment of acute kidney injury

The present invention relates to compounds of the formula I, wherein A, Y, Z, Rto R, Rto Rand Rhave the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPAreceptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.

Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals

The invention therefore relates to compounds of the formula I in which A, X, Y, R, Rand Rhave the given meanings. The compounds of the formula I are suitable, for example, for wound healing.

Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring

The invention relates to oxazolopyrimidine compounds of formula I, where A, Rand Rare defined as stated in the claims. The compounds of formula I are suitable, for example, for wound healing. 

2,5-substituted oxazolopyrimidine derivatives

The present invention relates to compounds of the formula I, wherein A, Y, Z, Rto Rand Rhave the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPAreceptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.

Acylamino-substituted cyclic carboxylic acid derivatives and their use as pharmaceuticals

Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring The invention therefore relates to compounds of the formula I in which X, Y, R, Rand Rhave the given meanings. The compounds of the formula I are suitable, for example, for wound healing.

Carboxylic acid derivatives having an oxazolo[4,5-c]pyridine ring

The present invention relates to oxazolopyrimidine compounds of the formula I, in which A, R, R, Rand X are defined as indicated in the claims. The compounds of the formula I modulate the activity of the Edg-1 receptor and in particular are agonists of this receptor, and are useful for the treatment of diseases such as atherosclerosis, heart failure or peripheral arterial occlusive disease, for example. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

Carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring

The invention relates to oxazolopyrimidine compounds of formula (I), where A, R, R, R, R, X and Y are defined as stated in the claims. The compounds of formula I are suitable, for example, for wound healing. 

Heterocyclic carboxylic acid derivatives having a 2,5,7-substituted oxazolopyrimidine ring

Heterocyclic carboxylic acid derivatives comprising a 2,5-substituted oxazolopyrimidine ring as Edg-1 receptor agonists The present invention relates to oxazolopyrimidine compounds of the formula I, in which A, R, R, R, X and Y are defined as indicated in the claims. The compounds of the formula I modulate the activity of the Edg-1 receptor and in particular are agonists of this receptor, and are useful for the treatment of diseases such as atherosclerosis, heart failure or peripheral arterial occlusive disease, for example. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

Heterocyclic carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring

The invention relates to oxazolopyrimidine compounds of formula (I), where A, R, Rand Rare defined as stated in the claims. The compounds of formula (I) are suitable, for example, for wound healing. 

2,5,7-substituted oxazolopyrimidine derivatives

The invention relates to oxazolopyrimidine compounds of formula (I), where A, R, R, R, Rand X are defined as stated in the claims. The compounds of formula I are suitable, for example, for wound healing. 

Carboxylic acid derivatives having a 2,5,7-substituted oxazolopyrimidine ring

The present invention relates to cycloalkyloxycarboxylic acid derivatives of the formula I in which A, R, R, R, R, Rand X are as defined in the claims. The compounds of the formula I are suitable, for example, for wound healing.

Cycloalkyloxycarboxylic acid derivatives

The present invention relates to oxazolopyrimidine compounds of the formula I in which A, R, Rand Rare defined as indicated in the claims. The compounds of the formula I modulate the activity of the Edg-1 receptor and in particular are agonists of this receptor, and are useful for the treatment of diseases such as atherosclerosis, heart failure or peripheral arterial occlusive disease, for example. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them. 

Oxazolopyrimidines as Edg-1 receptor agonists

The present invention relates to compounds of the formula I, wherein A, Y, Z, Rto Rand Rhave the meanings indicated in the claims, which are pharmaceutically active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPAreceptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.

Growing community of inventors

Frankfurt am Main, Germany

Matthias Schaefer